ArticleJIMD reports2019

Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion.

Rhona M Jack et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.